A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Jk, Weick; Kopecky, KJ; Appelbaum, FR; Head, DR; Kingsbury, LL; Sp, Balcerzak; Bickers, J.; Hynes, HE; Welborn, JL; Simon, S; R. Grever, Michael

doi:10.1182/blood.v88.8.2841.bloodjournal8882841

Public

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

Published in Blood • Oct 15, 1996

Authors:

Weick Jk

KJ Kopecky

FR Appelbaum

Abstract

Interest in high-dose cytarabine (HDAC) for both induction and postremission therapy for acute myeloid leukemia (AML) prompted the Southwest Oncology Group (SWOG) to initiate a randomized trial comparing HDAC with standard-dose cytarabine (SDAC) for remission induction of previously untreated AML an...

Subject

Cytarabine

Medicine

Daunorubicin

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!